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ABSTRACT 
Conjugated linoleic acid (CLA) supplementation has shown convincing effects at reducing body fat in animals; 
yet human study results have been somewhat inconclusive.  The purpose of this study is to determine whether 
four weeks of CLA supplementation, the approximate length of a commercial package, can result in a positive 
change in visceral adipose tissue in resistance-trained middle-aged men.  Thirty overweight and moderately 
obese, but otherwise healthy male subjects (aged 35 to 55 years) currently involved in resistance training, were 
randomly assigned into CLA and placebo groups in a double-blind, placebo controlled approach.  The study 
lasted for 12 weeks and consisted of three four-week periods.  During the first four weeks (run-in period) each 
subject received placebo (4 g safflower oil). Throughout the next four weeks (supplementation period), the 
placebo group continued receiving placebo, while the CLA group received 3.2 g/d of CLA.  During the final 
four weeks (run-out period) all subjects received the placebo.  Computed tomography (CT) scans were used to 
measure visceral adipose tissue (VAT) at weeks 4, 8 and 12.  No significant reduction in VAT cross-sectional 
area was determined in the CLA group during the study.  On the contrary, a significant reduction in cross-
sectional area of VAT of 23.12 cm
2 during the supplementation period was measured in the placebo group, 
which was abated during the run-out period.  Our results suggest that CLA supplementation of 3.2 g/d for four 
weeks does not promote decreases in VAT in middle-aged men currently participating in a resistance-training 
program.  Journal of the International Society of Sports Nutrition.  3(2): 28-36, 2006 
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INTRODUCTION 
 
The term conjugated linoleic acid (CLA) is a group 
of positional and geometric conjugated dienoic 
isomers of linoleic acid 
1.The term conjugation refers 
to the double bonds in the biochemical configuration 
of CLA.  These double bonds are conjugated, instead 
of being in the typical methylene interrupted 
configuration.  The conjugated double bonds occur at 
carbon atoms 9 and 11, or 10 and 12, with all 
possible cis and trans combinations.  However, the 
cis-9, trans-11 isomer and the trans-10, cis-12 isomer 
are the only CLA isomers bearing biological activity 
2.  These two isomers are predominately the focus of 
most current research in both animal and human 
studies, as well as the primary components of 
commercially available CLA mixtures.  All other 
positional and geometrical isomers of CLA are 
present in much lower concentrations in both 
commercially prepared and natural food products.   
Small quantities of CLA are found in the milk and 
meat of ruminant animals.  Food lipids originating 
from these animals, such as dairy and beef, contain 
much higher levels of CLA than lipids from non-
ruminant animals.  However, CLA is not found in 
substantial amounts in normal diets. 
 
In animal studies, conjugated linoleic acid has been 
shown to inhibit carcinogenesis and atherosclerosis 
3,4, enhance immunologic function while protecting 
against the catabolic effects of immune stimulation  
5,6, affect body composition change by reducing body 
fat gain while enhancing lean body mass gain 
7, and 
stimulate the growth of young rats 
8. In addition, 
CLA supplementation has also been shown to have 
an effect on fat partitioning 
9 and on the reduction of 
body fat measured by various methods 
10-13. Only a 
few human studies involving CLA supplementation 
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have been conducted and the results are inconsistent.  
Positive results on the effect of CLA on body fat 
mass 
14, percent body fat 
15, and sagittal abdominal 
diameter 
16 have been reported.  On the other hand, 
no change on percent body fat 
17-19 or fat mass 
16-25 
has been reported. The methods used in those reports 
were varied.  However, none of the investigators had 
used computed tomography (CT) scanning which is a 
direct method of measuring visceral adipose tissue.  
Regardless of the methods used to measure visceral 
adipose tissue, short-term studies of CLA 
supplementation have been shown to be safe 
14,21 and 
is one of the principle supplementation protocols 
used by people to lose body fat. Likewise, people 
engage in resistance exercise training to improve 
their body composition and general health. However, 
very little is known at this time related to the efficacy 
of CLA supplementation in the exercising population. 
Based on this the present study was designed to 
investigate the effects of CLA supplementation on 
visceral adipose tissue (VAT) of healthy overweight 
or moderately obese humans currently performing 
resistance training. VAT was specifically targeted 
based on its well established association with 
dyslipidemia, hypertension and diabetes 
26.
  The 
supplementation period lasted for four weeks which 
approximates a single package amount of the 
supplement. CT scanning was the method used to 
measure VAT in this randomized, double-blind, 
placebo-controlled study. 
METHODS 
 
Subjects. Thirty overweight (BMI >25 kg/m
2) male 
subjects were recruited and randomized into CLA 
and placebo groups (15 subjects/group). All 
participants were between 35 to 55 y old and   
healthy, non-smokers recruited from members of a 
personal fitness training center (The Studio, Dallas, 
Texas) and were engaged in a resistance-training 
program for at least six months prior to the beginning 
of the study.  A maintenance resistance-training 
program was supervised to control exercise as a 
confounding factor. Subjects who had unstable 
medical conditions or any clinical conditions that 
rendered them unfit to partake in the study, or were 
taking any medications or supplements for weight 
loss, were excluded. Approval from the Institutional 
Review Board at Texas Woman’s University was 
secured before the study was initiated.  Written 
informed consent from all participating subjects was 
obtained. 
 
Experimental design.  The study was a randomized, 
placebo-controlled, double-blind study in free-living 
healthy male volunteers currently performing 
resistance training.  The study lasted 12 weeks and 
consisted of three four-week periods.  During the first 
four-week period, the run-in period, each subject 
received four placebo capsules daily taken all at once, 
consisting of 1.0 g of safflower oil each, to accustom 
the subjects to taking capsules on a daily basis.   
During the next four-week period, the 
supplementation period, the randomly assigned 
subjects either received CLA (3.2 g CLA 
administered in four capsules daily, taken all at once 
with a meal) or if in the placebo group, continued 
receiving four  placebo capsules daily  taken all at 
once.  The final four-week period was a run-out 
period, during which all subjects were taking four 
placebo capsules daily.  Figure 1 is a chronological 
representation of the key activities during the study. 
 
CLA and Placebo Supplements.  Tonalin™ CLA and 
placebo capsules were donated by Cognis 
Corporation (LaGrange, Illinois).  Each Tonalin™
 
CLA capsule contained 1000 mg oil of which 
approximately 80% was CLA, with equal parts cis-9, 
trans-11 and trans-10, cis-12 isomers.  Table 1 shows 
the fatty acid composition of Tonalin
™ CLA capsules.  
Each placebo capsule contained 1000 mg high 
linoleic (>77% linoleic) safflower oil.  Both CLA and 
placebo capsules were transparent, caramel-colored, 
soft gelatin capsules identical in appearance.  All 
subjects met with the principle investigator on a 
weekly basis to receive one week’s supply of either 
the placebo or the CLA capsules and to return any 
unconsumed capsules.  Capsule counts were used to 
verify subject compliance.  All weekly allotments of 
both placebo and CLA capsules were the same with 
each subject receiving seven packages of four 
capsules each week.  In total, each subject met with 
the principle investigator 12 times during the course 
of the study. 
 
Anthropometric measurements. This was a focused 
trial investigating only changes in VAT due to its 
association with health risk. Body weight was 
measured throughout to determine body mass index 
(BMI), a commonly used indicator of health risk and 
a measurement that has been tied to the strength of 
VAT as an independent risk factor 
26. Body weight 
was measured using a calibrated electronic scale to 
the nearest 0.1 kilogram, with the subjects wearing 
light workout clothing and no shoes.  All subjects 
were weighed before any physical activity was 
performed.  Height was measured with a wall-
mounted height scale to the nearest 0.5 centimeter 
while the subjects were standing without shoes.  The  Journal of the International Society of Sports Nutrition. 3(2): 28-36 2006. (www.sportsnutritionsociety.org) 
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Figure 1.  Block diagram of CLA study timeline throughout 12 weeks of study.  FFQ = Food Frequency Questionnaire 
  
BMI was calculated as the body weight in kilograms 
divided by the square of the height in meters.  Weight 
was measured at week 0, week 4 (end of the run-in 
period), week 8 (end of the supplementation period), 
and week 12 (end of the run-out period). 
 
Table 1. Fatty acid composition of Tonalin™ CLA 
capsules
1. 
Ingredient Tonalin
™ CLA 
Fatty acid composition 
 
%
16:0 2.0 
18:0 2.7 
18:1 12.9 
18:2 0.6 
Others 2.2 
CLA isomers   
Total CLA  79.6 
  cis-9, trans-11 39.2 
  trans-10, cis-12 38.5 
 
 
 
Measurement of Visceral Adipose Tissue (VAT).  
VAT was measured using computed tomography 
(CT) scanning of the abdominal area.  Abdominal CT 
scans were taken at the end of the run-in period 
(week 4), the supplementation period (week 8), and 
the run-out period (week 12).  CT scanning was 
performed with all subjects in the supine position. 
Scanning was performed at 120 kV and 200 mA with 
a section slice thickness of 10 mm (scanning time of 
two seconds, field view of 400 mm).  CT scanning 
was performed at the Texas Imaging and Diagnostic 
Center in Dallas, Texas with the General Electric 
(Waukesha, WI) Hi Speed Computerized 
Tomography Scanner (Model # 46-30100G13).  
 
In all subjects, VAT areas were measured on one 
cross sectional scan obtained at the umbilicus, 
between the 4
th and 5
th lumbar vertebrae (L4-L5). The 
subjects were examined with arms stretched over 
their heads to minimize artifacts during the 
examinations.  Before every examination, the CT 
scanner was calibrated with water at room 
temperature of 20°C.  The region of interest, the 
intraperitoneal tissue, was defined by tracing its 
contour with a cursor on each scan.  The attenuation 
range of CT numbers (in Hounsfield units, HU) for 
fat tissue was used to distinguish adipose tissue from 
lean, organ and bone tissue.  A fixed attenuation 
range from –190 to –30 HU was used as the standard 
of reference, as defined by Sjöström et al 
27 and Kvist Journal of the International Society of Sports Nutrition. 3(2): 28-36 2006. (www.sportsnutritionsociety.org) 
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et al 
28. This attenuation range was put into the 
computer to enable VAT highlighting.  The pixels 
with attenuation values in the selected attenuation 
range were depicted as white.  From those white 
regions, the total VAT area was calculated by 
counting the number of pixels in each measured area.  
Figure 2 provides a sample of a typical CT scan after 
fat tissue highlighting techniques were applied, 
showing VAT in white.  The “1” shown in the CT 
scan is generated by the computer during the 
determination of fat tissue highlighting and indicates 
that only one encircled area is measured. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  A sample of a typical CT scan.  AW = 
abdominal wall; SAT = subcutaneous adipose tissue; VAT 
= visceral adipose tissue.  
 
 
Dietary assessment.  All subjects were asked to 
submit three-day dietary records and verbally 
complete a food frequency questionnaire at the 
beginning of the study (week 0) and at the 
completion of each four-week period, when they met 
with the principle investigator. The aim of both the 
dietary records and the questionnaire was to 
determine food consumption patterns that might 
influence body weight and composition as well 
providing additional sources of CLA. 
 
Physical training.  Subjects in both groups were 
instructed prior to the beginning of the study to 
continue their current resistance-training programs 
for no fewer than 12 weeks at The Studio, a personal 
fitness training facility, in Dallas, Texas.  Subjects 
came to The Studio two times per week for a total of 
24 training sessions during the 12-week investigation.  
Each resistance-training session lasted 55 minutes.   
Because of the individuality of training sessions, 
exact training protocols were not used; however 
training logs were maintained and certain exercises 
were required for inclusion in each training session. 
The resistance-training program included, but was 
not limited to, the following exercises:  chest press, 
lat pull down, shoulder press, bicep curl, triceps press 
down, leg press, and leg curl.  All resistance-training 
programs were supervised or administered by 
professional certified personal fitness trainers. 
 
Statistical methods. Data collected at the end of each 
four-week period (week 4 to week 12) was assessed 
using two-way ANOVA with repeated measures 
(2X4 design) with application of Fisher’s least 
significant difference post hoc analysis. Statistical 
significance was set at (P < 0.05). All statistical 
analyses were performed with the Statistical Package 
for the Social Sciences (SPSS) version 10.05 (SPSS 
Inc., Chicago, IL). 
SAT 
AW 
Umbilicus 
VAT 
 
 
RESULTS 
 
Data used for analysis were from 28 subjects because 
one subject was disqualified for noncompliance 
during week 3 (failed to take the capsules as 
required) and the second subject failed to have the 
second CT scan administered within the appropriate 
timeframe.  The demographic data of the subjects are 
shown in Table 2.  The age, BMI and weight of the 
subjects in the CLA group were similar to those of 
the placebo group at the time when the subjects were 
enrolled into the study (week 0). Both study groups 
had 100% compliance with taking their respective 
capsules.  The supplements were well tolerated in all 
subjects, with only a few subjects reporting mild 
nausea, which was alleviated by taking supplements 
with food. 
 
Table 2. Descriptive data of the study population 
after randomization
1,2. 
Group Age  Height  Weight  BMI 
  y Cm kg kg/m
2
        
Placebo 
(n=13) 
43.8 ± 4.2  177 ± 6  95.2 ± 13.8  30.4 ± 4.6 
        
CLA (n=15) 
 
43.4 ± 6.0  179 ± 8  97.0 ± 16.5  30.3 ± 4.4 
 
1 Values are mean ± SD.  None of the parameters were 
significantly different (p > 0.05) between the two treatment 
groups using paired t-test.  
2 Measurements were made at week 0 before randomization 
procedure. 
 Journal of the International Society of Sports Nutrition. 3(2): 28-36 2006. (www.sportsnutritionsociety.org) 
 
32
Body weight and body mass index (BMI).  Before 
supplementation began (week 0), the two groups of 
subjects did not differ significantly in either body 
weight or BMI (Table 3).  At the end of the run-in 
period (week 4), the placebo group had gained an 
average of 1 kg, which is statistically heavier than the 
body weight at week 0.    Neither of the two groups 
had a significant change in weight or BMI after four 
weeks of treatment (week 8).  No residual effect of 
CLA on either the weight or BMI (Table 3) was 
found.  No significant difference in weight or BMI 
between placebo and CLA groups at any of the time 
periods was found during the course of the study. 
 
 
Table 3. Body weight and BMI of overweight men 
participating in a RT program given placebo or CLA 
during a 12-week supplementation study
1
 Group  Week
2
   0  4  8  12 
Body 
weight 
(kg) 
        
 Placebo   
(n=13) 
95.2 ± 
13.8 
96.2 ± 
13.8* 
96.3 ± 
14.2 
96.5 ± 
14.8 
          
 CLA   
(n=15) 
97.0 ± 
16.5 
97.5 ± 
16.2 
97.3 ± 
16.1 
97.6 ± 
16.4 
          
BMI 
(kg/m
2) 
        
 Placebo   
(n=13) 
30.4 ± 
4.6 
30.7 ±    
4.6 
30.7 ± 
4.6 
30.8 ± 
4.8 
          
 CLA   
(n=15) 
30.3 ± 
4.4 
30.4 ±   
4.4 
30.4 ± 
4.4 
30.5 ± 
4.5 
1 Values are mean ± SD.  * Significantly different from week 0, P 
< 0.05 (paired t-test). 
2 Week 0 = baseline; Week 4 = end of placebo period for all 
subjects (run-in period); Week 8 = end of the CLA and placebo 
periods (supplementation period); Week 12 = end of placebo 
period for all subjects (run-out period). 
 
 
Visceral adipose tissue (VAT).  There was no 
significant reduction (-9.79 cm
2) of the VAT area 
after four weeks of CLA consumption at 3.2 g/day.  
However, a significant reduction (-23.12 cm
2) of 
VAT area in the placebo group was determined at the 
end of the supplementation period (Table 4).  During 
the run-out period both groups resumed the daily 
consumption of four placebo capsules; no significant 
changes in either group of subjects were observed.  
There was no between groups significant difference 
in the VAT area at any time period. 
 
Dietary analysis. All participants completed all four 
of the food frequency questionnaires.  Responses to 
the questionnaire suggest and statistical analysis 
demonstrated that the subjects did not significantly 
change their eating habits during the course of the 
study with regard to the frequency of meals, 
consumption of red meat and foods containing high 
amounts of CLA, and whether or not they were 
currently dieting (Table 5).   
 
DISCUSSION 
 
Healthy, middle-aged, overweight or moderately 
obese men fed 3.2 g/d of CLA for four weeks showed 
no significant change in visceral adipose tissue 
(VAT) measured by computed tomography (CT) 
scanning.  This finding is in contrast to several 
previous reports.  Blankston et al. 
14 reported a 
significant reduction of body fat mass (BFM) in 
overweight and moderately obese healthy men and 
women volunteers who consumed 3.4 g/d or 6.8 g/d 
CLA for 12 weeks.  Smedman and Vessby 
15 reported 
a borderline significant (P=0.05) reduction in the 
percent body fat of normal weight subjects fed CLA 
(4.2 g/d for 12 weeks) as compared to the placebo 
group.  However, they did not find a significant 
change in sagittal abdominal diameter (SAD) 
between the two groups. The number of subjects 
included in their study was 24 for the CLA group and 
26 for the placebo group.  Risérus et al. 
16 reported a 
significant decrease in SAD of men fed 4.2 g/d CLA 
for four weeks compared to those in the placebo 
group.  These subjects were described as abdominally 
obese (BMI ≅ 32) and were between the ages of 39 
and 64 y.  These subjects were similar to the subjects 
in our study except they were not engaged in an 
exercise regimen.  The average change in the SAD 
for the CLA group was from 29.5 to 28.9 cm while 
no change was found in the placebo group.  In their 
discussion of results these investigators of this study 
acknowledged that the method of CT scanning is 
superior to the method of SAD and suggested that 
their results needed confirmation by CT scanning.   
To our knowledge, the present study is the first to 
assess the effect of CLA supplementation on visceral 
fat using CT scanning.   In our study we used a single 
slice of VAT located between L4 and L5, which was 
believed to provide an accurate assessment of VAT. 
Meanwhile, Shen et al. 
29 have recently suggested 
that group comparisons of VAT volume using CT 
scanning may be carried out by using a single-slice 
VAT area located 10 cm above L4-L5 in men. Future 
research efforts should involve multiple 
measurements and clarify a standard of assessment. 
In our study, the change of VAT within each group 
showed that the placebo group had a significantly 
lower VAT whereas the loss in the CLA group did 
not reach a significant level during the four weeks of   
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Table 4.  Visceral adipose tissue (VAT) of overweight men participating in a resistance-training program given 
placebo or CLA during a 12-week study
1
 
Group Week
2   
 4  8  12  Change  wk 
 4-8 
Change 
 wk 8-12 
 cm
2 cm
2 cm
2 cm
2 cm
2
          
Placebo 
(n=13) 
167.25 ± 87.96  144.13 ± 
84.96* 
144.32 ± 
89.18* 
-23.12 ± 21.60  0.19 ± 18.11 
          
CLA 
(n=15) 
172.17 ± 82.93  162.37 ± 98.39  166.91 ± 94.46  -9.79 ± 28.62  2.73 ± 14.99 
 
 
1 Values are mean ± SD.  *Significantly different from week 4, P < 0.05 (paired t-test). 
2 Week 4 = end of placebo period for all subjects (run-in period); Week 8 = end of the CLA and placebo periods (supplementation  
   period); Week 12 = end of placebo period for all subjects (run-out period). 
 
 
 
Table 5.  Food questionnaire data of placebo and CLA groups
1,2,3 
 
Question  Week  Placebo (n=13)  CLA (n=15) 
Number of meals per day 
  0  3.54 ± 0.78  3.60 ± 0.91 
  4  3.54 ± 0.78  3.67 ± 0.82 
  8  3.46 ± 0.66  3.60 ±0.91 
  12  3.31 ± 0.48  3.53 ± 0.83 
      
Number of times consuming red meat per week 
  0  2.92 ± 1.38  3.53 ± 1.13 
  4  2.92 ± 1.19  3.40 ± 1.18 
  8  2.77 ± 1.01  3.33 ± 0.98 
  12  2.38 ± 1.33  3.20 ± 1.08 
      
Number of times consuming whole dairy products per week 
  0  2.69 ± 1.65  2.60 ± 1.40 
  4  2.46 ± 1.45  2.60 ± 1.30 
  8  2.69 ± 1.38  2.60 ± 1.06 
  12  2.77 ± 1.36  2.73 ± 1.39 
      
Currently on diet (Yes = 1; No = 2) 
  0  2.00 ± .00  1.80 ± .41 
  4  2.00 ± .00  1.87 ± .35 
  8  2.00 ± .00  1.87 ± .35 
  12  1.85 ± .38  1.87 ± .35 
      
Length of dieting in weeks 
  0  0.00 ± .00  0.73 ± 1.62 
  4  0.00 ± .00  0.67 ± 1.76 
  8  0.00 ± .00  0.67 ± 1.76 
  12  0.38 ± 1.12  0.67 ± 1.76 
 
1 Values are mean ± SD.   
2 Calculations of values assigned to questionnaire answers were made after submission of each questionnaire (wk 0, 4, 8 and 12).
  
3 No statistical differences were determined (wk 0, 4, 8 and 12). 
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supplementation.  The placebo group had lost an 
average of 23.12 cm
2 and the CLA group had lost 
9.79 cm
2.   However, because no significant 
difference in VAT was observed between CLA and 
placebo group, the difference in the placebo group is 
believed to represent a slightly greater effect of 
involvement in a research project itself and/or 
experimental error.    
 
The results of our study are in contrast to some 
related studies involving CLA supplementation in 
adults. For instance, Thom et al. 
30 reported a 
significant reduction in percent body fat of CLA 
subjects who did regular physical training after 
consuming CLA (1.8 g/d) for 4, 8, or 12 weeks.   
These subjects were younger (18-30 y) with lower 
BMI (25 kg/m
2) than the subjects in our study.  A 
significant reduction in percent body fat was also 
reported by Mougios et al. 
31  in young men and 
women (19-24 y) after receiving 0.7 g/d of CLA for 
four weeks followed by 1.4 g/d for four weeks.   
Concomitant decreases in percent body fat and sum 
of the thickness of 10 skinfolds were observed during 
the high CLA intake period.  
 
On the other hand, CLA supplementation (6.2 g/d) 
for four weeks did not promote significant changes in 
percent body fat or fat mass of experienced, 
resistance-trained young men as reported by Kreider 
et al. 
17. Lowery et al. 
22 showed that CLA 
supplementation of 7.2 g per day for six weeks 
during resistance training significantly increased arm 
mass and body mass with no differences observed in 
skinfold or bioelectrical impedance-determined body 
fat.  The researchers suggested that the gains in 
weight were apparently due to an increase in fat-free 
mass and not a decrease in fat mass.  Kamphuis et al. 
23,24 concluded that a 13-week CLA supplementation 
(1.8 g/d or 3.6 g/d) after a 3-week very-low-calorie 
diet (VLCD) did not improve weight maintenance.   
In one of the largest published trials on the effects of 
CLA on body composition 
21, no significant change 
of either body fat mass or percentage of body fat was 
found in the CLA group regardless of the dose (1.5 
g/d or 2 g/d) and the form of CLA isomers (cis-9, 
trans-11 or trans-10,  cis-12).  The subjects were 
moderately obese (BMI 25 to 30 kg/m
2) and the 
length of the study was 18 weeks.  The percent body 
fat was assessed by dual-energy X-ray 
absorptiometry (DEXA), which is considered an 
accurate, precise and reproducible method 
32. 
Similarly, Risérus et al. 
33 also did not find the effect 
of 3.4 g of trans-10 cis-12 CLA supplementation for 
12 weeks on body weight and fat mass in obese 
subjects. Likewise Zambell et al. 
20 were not able to 
demonstrate any significant effects of CLA 
supplementation (3 g/d) on body composition in adult 
women in a 64-day study.  Percent body fat was not 
significantly reduced after eight weeks of CLA 
supplementation either at 4 g/d 
18 or 3.4 g/d 
19. 
Additionally, no significant reduction of body fat was 
found by Atkinson 
25 in a six-month CLA (2.7 g/d) 
supplementation study. 
 
Gaullier et al. 
34 was the first group to document the 
long-term (12 months) safety and efficacy of CLA 
supplementation in overweight subjects.  These 
investigators found a significant lowering of body fat 
mass assessed by DEXA scanning.  There were 
almost five times as many women as men in their 
study.  After a best-responder analysis, the greatest 
effect of CLA supplementation was present in 
women with the highest BMI. 
 
To our knowledge, our study was also the first one to 
examine whether there could be a residual effect of 
CLA supplementation by including a four-week, 
post-supplementation run-out period.  We did not 
find any significant difference of VAT area, either 
within groups or between groups during the run-out 
period (Table 4).  In addition, our investigation 
included multiple three-day dietary records in an 
attempt to rule out diet as an experimental variable.   
Based on our analysis no significant changes were 
observed for any of the nutrient intakes between and 
within groups except for the intake of 
monounsaturated fat.  The CLA group consumed a 
significantly higher amount of monounsaturated fat 
than the placebo group during week 4.  However, 
firm conclusions based on dietary consumption in 
this study are extremely difficult based on the small 
number of subjects who completed and turned in all 
the required dietary records.  The majority of our 
subjects were business professionals that dined out of 
the house for most of their meals.  This made 
recording of dietary intake extremely difficult, which 
may explain our low success rate in obtaining 
complete dietary records.  All 28 subjects completed 
the food frequency questionnaires.  Data from the 
questionnaires showed that the subjects did not 
significantly change their eating habits during the 
course of the study with regard to the frequency of 
meals, consumption of red meat and foods containing 
high amounts of CLA, and whether or not they were 
currently dieting.  Questionnaires were given orally 
to subjects throughout the study; this can account for 
the high success rate of completion.  Therefore, food 
frequency questionnaires may be a better tool for 
obtaining nutrient intake information, eating 
preferences, meal frequency, dietary habits, and Journal of the International Society of Sports Nutrition. 3(2): 28-36 2006. (www.sportsnutritionsociety.org) 
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general food consumption details in a free-living 
experimental design than requiring subjects to submit 
detailed food records.  One limitation to the food 
frequency questionnaires was that alcohol intake was 
not surveyed.  Visceral adipose tissue has been 
shown to increase in alcoholic men 
35. Therefore, 
failure to monitor consumption of alcohol among the 
subjects, especially the CLA group, may have 
contributed to our findings. 
 
All the published reports on the effect of CLA 
consumption on body fat mass or percent body fat 
varied in the age of the subjects, the dose of CLA 
given, the exercise regimen, and the methods used to 
determine body fat.  None of the studies had used CT 
scanning to assess visceral adipose tissue.  The 
methods of measuring body fat used in the other 
studies were mostly indirect methods.  It is therefore 
difficult to compare our data to those published ones 
because of the differences among the studies.   
 
One major parameter that could help identify the 
effects of CLA supplementation on body fat is the 
method chosen to determine body fat.  More precise 
methods such as the CT scanning or DEXA scanning 
should be used to determine body fat.  These methods 
have less chance for error and provide a more direct 
assessment of body fat.  Very little consistency has 
been found in published human studies examining the 
effects of CLA on body fat.  While the effects in 
animal studies are quite clear, human studies offer no 
clear explanation or reliable findings.   
 
The data presented in our study does not support the 
notion that CLA supplementation promotes visceral 
fat loss in middle-aged men already performing 
resistance-training exercises. However, it needs to be 
recognized that the participants received CLA in one 
daily dose instead of split doses at different times. 
Future studies might want to clarify whether 
separating the dose can influence the efficacy of CLA 
supplementation on VAT. Furthermore, the design of 
this study required that each subject performed a 
maintenance resistance training program throughout 
the study to simulate a “real world” manner in which 
CLA might be used by an exercising population. 
While certain exercises were required to be a part of 
each subject’s workouts, the variance between each 
subject’s workouts may have influenced our findings. 
Future research projects that involve exercise might 
want to consider a standardized training protocol 
before initiating the supplementation trial.  
 
In conclusion, the results of this study do not suggest 
that CLA supplementation is an effective means of 
lowering VAT, and thus health risk, in previously 
exercising middle-aged overweight men. However, 
further human research is needed in various 
experimental conditions in order to draw a more 
confident conclusion. 
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